New U.K. NHS Bodies Authorize Avastin Use In AMD As Lucentis Pricing Pressures Continue
You may also be interested in...
Italy's Move To Fund Off-label Avastin Use In AMD May Be Illegal, Pharma Groups Say
EFPIA, Novartis and Roche believe that a decision by the Italian regulatory authority, AIFA to allow reimbursement for the off-label use of Avastin in place of Lucentis may be against EU law.
Italy Wants €1.2 Billion From Novartis And Roche In Lucentis/Avastin Saga
The Italian government has said it will pursue Roche and Novartis for €1.2 billion it says the Swiss companies owe to its health service for anticompetitive activities involving Avastin and Lucentis.
EMA Looks At Avastin, As Novartis/Roche Appeal Italian Competition Fines
With EMA deliberating about Avastin, Novartis and Roche have confirmed that they will appeal the €180.5 million fine imposed on them by Italy’s competition authority for anti-competitive behavior.